Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
significant barrier » significant burden (Expand Search)
barrier decrease » larger decrease (Expand Search), barrier disease (Expand Search), marked decrease (Expand Search)
Showing 641 - 660 results of 21,342 for search '(( significant decrease decrease ) OR ( significant barrier decrease ))', query time: 0.39s Refine Results
  1. 641
    Mean standard errors across time points for the outcome of social stigma.

    Mean standard errors across time points for the outcome of social stigma. by Ana Beato (20489933)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  2. 642
    Means with standard errors across time points for the outcome of social distance.

    Means with standard errors across time points for the outcome of social distance. by Ana Beato (20489933)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  3. 643
    Means with standard errors across time points for the outcome of intergroup anxiety.

    Means with standard errors across time points for the outcome of intergroup anxiety. by Ana Beato (20489933)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  4. 644
    Characteristics of the sample.

    Characteristics of the sample. by Ana Beato (20489933)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  5. 645
    Table 1_Increased frequencies of human Th-17 CD4+ T-cells and decreased T-regulatory cells in patients with early and advanced metabolic dysfunction-associated steatotic liver disease.docx

    Table 1_Increased frequencies of human Th-17 CD4+ T-cells and decreased T-regulatory cells in patients with early and advanced metabolic dysfunction-associated steatotic liver dise... by Elżbieta Supruniuk (16736637)

    Published 2025
    Save to List
    Saved in:
  6. 646
    Table 2_Increased frequencies of human Th-17 CD4+ T-cells and decreased T-regulatory cells in patients with early and advanced metabolic dysfunction-associated steatotic liver disease.xlsx

    Table 2_Increased frequencies of human Th-17 CD4+ T-cells and decreased T-regulatory cells in patients with early and advanced metabolic dysfunction-associated steatotic liver dise... by Elżbieta Supruniuk (16736637)

    Published 2025
    Save to List
    Saved in:
  7. 647
    Comparative Analysis of Chills Experience Across Three Groups: This table presents a detailed comparison of three groups (A, B, and C) in terms of their experiences with chills. It includes the number of participants in each group, frequency, intensity, and duration of chills, along with demographics such as gender, age, race, education level, and income. Statistical significance (p-value) is also provided for each category.

    Comparative Analysis of Chills Experience Across Three Groups: This table presents a detailed comparison of three groups (A, B, and C) in terms of their experiences with chills. It... by Felix Alexandre Schoeller (20988295)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 648
    <i>N. parisii</i> infection is not significantly changed in <i>C. elegans</i> sphingolipid biosynthesis mutants.

    <i>N. parisii</i> infection is not significantly changed in <i>C. elegans</i> sphingolipid biosynthesis mutants. by Hala Tamim El Jarkass (16625309)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 649
    Two-way ANCOVA results for Task 1. The bold values highlight statistically significant results of Task 1.

    Two-way ANCOVA results for Task 1. The bold values highlight statistically significant results of Task 1. by Mucahit Gemici (21519313)

    Published 2025
    Save to List
    Saved in:
  10. 650
    One-way ANCOVA results for Task 2. The bold values highlight statistically significant results of Task 2.

    One-way ANCOVA results for Task 2. The bold values highlight statistically significant results of Task 2. by Mucahit Gemici (21519313)

    Published 2025
    Save to List
    Saved in:
  11. 651
    Summary of post-treatment disease course measures from MDMA-AT publications.

    Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 652
    Study selection criteria.

    Study selection criteria. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 653
    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.

    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 654
    Disease course measures after the PTSD treatments.

    Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 655
    PICOS criteria for the SLR.

    PICOS criteria for the SLR. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 656
    Summary of post-treatment CAPS score changes from MDMA-AT publications.

    Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 657
    Summary of post-treatment disease course measures from off-label medications clinical trials.

    Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 658
    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies.

    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 659
    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes.

    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 660
    Summary of post-treatment disease course measures from clinical trials with psychotherapies.

    Summary of post-treatment disease course measures from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: